INVESTIGATING THE RELATIONSHIP BETWEEN SERUM PENTRAXIN3 LEVEL AND ANGIOGRAPHIC FINDINGS IN PATIENTS WITH CORONARY ANGIOGRAPHY
DOI:
https://doi.org/10.22159/ajpcr.2018.v11i3.23011Keywords:
Pentraxin, Coronary angiography, Syntax scoreAbstract
 Objective: Pentraxin3 (PTX3) is an inflammatory single-phase mononuclear polysorbate glycoprotein, synthesized by endothelial, macrophages, and mildew cells; based on reports and research findings, it is also believed to be synthesized in the tissue of atherosclerotic lesions of arterial arteries. Therefore, PTX3 can be considered as a more specific marker for atherosclerosis. The present study examines the relationship between PTX3 serum levels and coronary angiography findings.
Methods: A total of 100 patients with stable cardiac status under elective coronary angiography were studied. Meanwhile, serum levels of PTX3 were measured, along with coronary angiography, in these patients. Finally, the relationship between the serum level of this marker and the severity of the angiographic findings of these individuals was compared and contrasted.
Results: out of 100 patients examined in the present study, 57 subjects (57.6%) were male and 42 subjects (42.4%) were female. The mean age of participants turned out to be 53±9.16, and the mean serum level of PTX3 was 5.91±12.5. The mean serum level of PTX3 turned out to be lower in patients with normal angiography than in those with coronary artery disease (p<0.0001). Smoking and age did not affect the mean serum levels of this marker. Furthermore, a higher serum level of PTX3 was associated with a higher syntax score in the angiography (p<0.0001).
Conclusion: Serum levels of PTX3 can have a predictive value in the diagnosis of coronary artery disease in patients with stable cardiovascular symptoms.
Downloads
References
Murray CJ, Lopez AD. Global mortality, disability, and the contribution of risk factors: Global burden of disease study. Lancet 1997;349:1436-2.
World Health Organization. World Health Report 1999 Making a Difference. Geneva: World Health Organization; 1999. Available from: http://www.who.int/whr/1999/en whr99_en. [Last accessed on 2014 Jun 25].
Liuzzo G. Atherosclerosis: An inflammatory disease. Rays 2001;26:221-30.
Maseri A, Fuster V. Is there a vulnerable plaque? Circulation 2003;107:2068-71.
Garlanda C, Bottazzi B, Bastone A, Mantovani A. Pentraxins at the crossroads between innate immunity, inflammation, matrix deposition, and female fertility. Annu Rev Immunol 2005;23:337-66.
Maugeri N, Rovere-Querini P, Slavich M, Coppi G, Doni A, Bottazzi B, et al. Early and transient release of leukocyte pentraxin 3 during acute myocardial infarction. J Immunol 2011;187:970-9.
Reid PC, Ito Y, Miyauchi K, Mantovani A. Pentraxin and female fertility. Ann Rev Immunol 2005;23:337-66.
Savchenko A, Imamura M, Ohashi R, Jiang S, Kawasaki T, Hasegawa G, et al. Expression of pentraxin 3 (PTX3) in human atherosclerotic lesions. J Pathol 2008;215:48-55.
Inoue K, Sugiyama A, Reid PC, Ito Y, Miyauchi K, Mukai S, et al. Establishment of a high sensitivity plasma assay for human pentraxin3 as a marker for unstable angina pectoris. Arterioscler Thromb Vasc Biol 2007;27:161-7.
Latini R, Maggioni AP, Peri G, Gonzini L, Lucci D, Mocarelli P, et al. Prognostic significance of the long pentraxin PTX3 in acute myocardial infarction. Circulation 2004;110:2349-54.
Knoflach M, Kiechl S, Mantovani A, Cuccovillo I, Bottazzi B, Xu Q, et al. Pentraxin-3 as a marker of advanced atherosclerosis results from the bruneck, ARMY and ARFY studies. PLoS One 2012;7:e31474.
Doganer YC, Aydogan U, Aydogdu A, Parci M, Akbulut H, Nerkiz P, et al. Relationship of Cystatin C with coronary artery disease and severity. Coron Artery Dis 2013;24:119-26.
George SJ, Lyon J. Pathogenesis of atherosclerosis. In: George SJ, Johnson J, editors. Atherosclerosis: Molecular and Cellular Mechanisms. Weinheim: Wiley-VCH; 2010. p. 3-14.
Nerkiz P, Doganer YC, Aydogan U, Akbulut H, Parlak A, Aydogdu A, et al. Serum pentraxin-3 level in patients who underwent coronary angiography and relationship with coronary atherosclerosis. Med Princ Pract 2015;24:369-75.
Haibo L, Xiaofang G, Chunming W, Jie Y, Guozhong C, Limei Z, et al. Prognostic value of plasma pentraxin-3 levels in patients with stable coronary artery disease after drug-eluting stent implantation. Mediators Inflamm 2014;2014:963096.
Tomandlova M, Jarkovsky J, Tomandl J, Kubkova L, Kala P, Littnerova S, et al. Prognostic value of pentraxin-3 level in patients with STEMI and its relationship with heart failure and markers of oxidative stress. Dis Markers 2015;2015:159051.
Alipour-Parsa S, Haybar H, Namazi MH, Safi M, Khaheshi I, Memaryan M, et al. Evaluation of pentraxin-3 level and its related factors in patients undergoing primary percutaneous coronary intervention. ARYA Atheroscler 2017;13:73-8.
Mirvete R, Mirela M, Ela P, Ledjan M. Comparison of reteplase double-bolus administration with streptokinase in acute myocardial infarction. Int J Pharm Pharm Sci 2015;7:180-3.
Gavishiddappa AH, Ishwar BB, Balappa MB, Shardha BR. Study on variations in the branching pattern of arch of aorta. Int J Pharm Pharm Sci 2015;7:515-7.
Published
How to Cite
Issue
Section
The publication is licensed under CC By and is open access. Copyright is with author and allowed to retain publishing rights without restrictions.
